Eric M. Dube Sells 11,375 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric M. Dube sold 11,375 shares of the business's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $24.04, for a total value of $273,455.00. Following the transaction, the chief executive officer now owns 419,173 shares in the company, valued at approximately $10,076,918.92. This trade represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Travere Therapeutics Trading Down 3.4 %

Shares of NASDAQ TVTX traded down $0.81 during mid-day trading on Friday, hitting $22.91. The company had a trading volume of 1,466,790 shares, compared to its average volume of 1,303,585. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 1-year low of $5.12 and a 1-year high of $25.29. The business's 50-day simple moving average is $19.22 and its 200 day simple moving average is $16.14.

Institutional Trading of Travere Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TVTX. RA Capital Management L.P. acquired a new stake in Travere Therapeutics in the fourth quarter valued at $20,033,000. Jennison Associates LLC purchased a new stake in Travere Therapeutics in the 4th quarter valued at approximately $14,222,000. Renaissance Technologies LLC boosted its holdings in Travere Therapeutics by 28.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,409,514 shares of the company's stock valued at $41,974,000 after purchasing an additional 534,500 shares in the last quarter. Invesco Ltd. lifted its position in shares of Travere Therapeutics by 135.2% during the 4th quarter. Invesco Ltd. now owns 858,942 shares of the company's stock valued at $14,963,000 after acquiring an additional 493,736 shares during the period. Finally, abrdn plc acquired a new position in shares of Travere Therapeutics during the 4th quarter worth approximately $6,829,000.

Analyst Ratings Changes

TVTX has been the topic of several research analyst reports. Barclays boosted their price target on Travere Therapeutics from $18.00 to $20.00 and gave the company an "overweight" rating in a research note on Friday, November 1st. Wells Fargo & Company raised Travere Therapeutics from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $9.00 to $27.00 in a report on Monday, October 21st. Cantor Fitzgerald started coverage on Travere Therapeutics in a report on Friday, January 10th. They set an "overweight" rating for the company. HC Wainwright upped their price target on Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a research report on Wednesday, January 15th. Finally, Evercore ISI increased their price objective on Travere Therapeutics from $33.00 to $45.00 and gave the stock an "outperform" rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Travere Therapeutics has an average rating of "Moderate Buy" and an average price target of $27.77.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.